— Chad Cohen will step down as CFO of Adaptive Biotechnologies on Feb. 15. Prior to joining Adaptive in 2015, Cohen was CFO of Zillow Group.
Principal accounting officer Kyle Piskel will serve as interim CFO after Cohen resigns. Cohen will work with Piskel and Adaptive in a consulting capacity during the transition, as Adaptive searches for a permanent CFO.
Adaptive pulled in more than $150 million in estimated revenue for 2021. That’s compared to $98.4 million for 2020, according to a statement announcing preliminary revenue results and Cohen’s departure.
Adaptive has experienced rapid growth during the pandemic, doubling its workforce and opening a new headquarters building in Seattle’s South Lake Union neighborhood last year. The company sells kits to assess the immune response and detect COVID-19, blood cancers, and other conditions, and partners with vaccine makers and other drug companies.
Cohen is also a board member of Vacasa, the vacation rental management platform company, and operating partner of Cota Capital, a San Francisco-based investment firm.
— Microsoft and Amazon veteran Joseph Sirosh was appointed to the Absci board. Sirosh is currently CTO of real estate platform company Compass. Sirosh previously served as CTO, corporate vice president of AI at Microsoft and is also a former vice president at Amazon.
Vancouver, Wash.-based Absci deploys AI and other computational methods, as well as laboratory screening techniques, to help drug companies find and develop protein-based drugs.
The recently-public biotech company also has announced a new partnership with long-time collaborator Merck. Absci will develop enzymes matched to biomanufacturing applications at Merck. Merck also has the option to enter into a drug discovery collaboration for up to three targets, which could yield up to $610 million in upfront fees and milestone payments for Absci.
— Kenneth Galbraith was appointed CEO of Zymeworks. Galbraith will replace co-founder Ali Tehrani, who has served as president and CEO since 2003.
From 2009 to 2013 Galbraith served on the board of Zymeworks, which has operations in Seattle and Vancouver, B.C. Most recently, Galbraith was executive-in-residence of Syncona, a British healthcare investment trust focused on the life sciences. He launched his biotech career at Vancouver-based biopharma company QLT, where he departed as CFO in 2000.
Zymeworks has several agents in clinical trials against cancer, including a “bispecific antibody” that recognizes immune cells and direct them to recognize and attack cancer cells. It also has a partnership with Bristol Myers Squibb, whose Seattle operation is developing new immune-mediated anti-cancer drugs. Galbraith will take the helm of Zymeworks in January, according to a statement.